Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-663513 + paclitaxel + carboplatin
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BMS-663513 + paclitaxel + carboplatin is an investigational combination therapy comprised of BMS-663513 (urelumab), a fully humanized IgG4 monoclonal antibody targeting CD137 (4-1BB); paclitaxel, a microtubule-stabilizing cytotoxic agent; and carboplatin, a DNA-damaging platinum-based chemotherapeutic. BMS-663513 acts as an agonist for CD137, providing a costimulatory signal to T cells that enhances interferon-gamma production and cytolytic activity, potentiating anti-tumor immunity[1][3]. Paclitaxel disrupts microtubule dynamics, inhibiting cell division, while carboplatin crosslinks DNA, causing apoptosis in rapidly dividing cells[2][4]. The combination has been evaluated for synergistic effects in advanced solid tumors, particularly aiming to enhance immunotherapy efficacy with cytotoxic chemotherapy[1][5].
- Other names
- urelumabpaclitaxelcarboplatin
02
Targets
MicrotubuleTNFRSF9 (CD137 extracellular domain)DNA
Beyond the preview
Go deeper on BMS-663513 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-663513 + paclitaxel + carboplatin.